Related Experiment Video
Updated: Sep 30, 2025

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
Published on: February 8, 2022
Atrial Cardiopathy and Cryptogenic Stroke
Yuji Kato1, Shinichi Takahashi1
1Department of Neurology and Cerebrovascular Medicine, Saitama Medical University International Medical Center, Hidaka, Japan.
Insights
Atrial cardiopathy, characterized by atrial dysfunction, can cause stroke before atrial fibrillation (AF) develops. Identifying this condition may prevent cryptogenic strokes.
Area of Science:
- Cardiology
- Neurology
- Pathophysiology
Background:
- Pathophysiological advances suggest atrial substrate abnormalities can lead to embolic stroke independently of atrial fibrillation (AF).
- Atrial cardiopathy, defined as atrial structural and functional disorders, may precede AF development and contribute to stroke risk.
- Cryptogenic stroke, a stroke of unknown origin, may be linked to underlying atrial cardiopathy.
Purpose of the Study:
- To provide a comprehensive overview of atrial cardiopathy and its association with cryptogenic stroke.
- To summarize current knowledge on the pathogenesis, biomarkers, and therapeutic interventions for atrial cardiopathy.
- To explore the potential of atrial cardiopathy as a therapeutic target for stroke prevention.
Main Methods:
- A narrative review of studies identified through a PubMed database search.
- Synthesis of recent findings on atrial cardiopathy, including its pathophysiology, diagnostic markers, and clinical implications.
- Analysis of the relationship between atrial cardiopathy and cryptogenic stroke, and potential treatment strategies.
Main Results:
- Atrial cardiopathy can cause embolic strokes before the clinical manifestation of AF.
- Promising biomarkers for atrial cardiopathy include P-wave terminal force in lead V1, N-terminal pro-brain natriuretic peptide, and left atrial enlargement.
- Atrial cardiopathy is considered a spectrum disorder, and its role as a therapeutic target is under investigation.
Conclusions:
- Atrial cardiopathy represents a significant substrate for embolic stroke, potentially explaining cryptogenic strokes in some patients.
- Further research is needed to establish optimal diagnostic criteria and therapeutic targets for atrial cardiopathy.
- The ARCADIA trial is investigating atrial cardiopathy as a target for anticoagulation therapy to prevent stroke.
Abstract:
Recent advances in pathophysiology suggest that a pathological atrial substrate can cause embolic stroke even in patients without atrial fibrillation (AF). This pathological condition is called "atrial cardiopathy", which indicates atrial structural and functional disorders that can precede AF. The objective of this narrative review was to provide a current overview of atrial cardiopathy and cryptogenic stroke. We searched the PubMed database and summarized the recent findings of the identified studies, including the pathogenesis of atrial cardiopathy, biomarkers of atrial cardiopathy, relationship between atrial cardiopathy and cryptogenic stroke, and therapeutic interventions for atrial cardiopathy. Abnormal atrial substrate (atrial cardiopathy) that leads to AF can result in embolic stroke before developing AF, and may explain the source of cryptogenic stroke in some patients. Although there are several potential biomarkers indicative of atrial cardiopathy, P-wave terminal force in lead V1 (>5,000 μV* ms), N-terminal pro-brain natriuretic peptide (>250 pg/ml), and left atrial enlargement are currently promising biomarkers for the diagnosis of atrial cardiopathy. Because the optimal combination and thresholds of biomarkers for diagnosing atrial cardiopathy remain uncertain, atrial cardiopathy represents a spectrum disorder. The concept of atrial cardiopathy appears to be most valuable as a starting point for therapeutic intervention to prevent stroke. Validation of the diagnosis of atrial cardiopathy and whether it can be used as a new therapeutic target for direct oral anticoagulants are currently being covered in the ARCADIA trial.
More Related Videos
08:10Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
08:56Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
Published on: September 24, 2021
Related Concept Videos
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Cardiomyopathy IV: Restrictive Cardiomyopathy
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Rheumatic Heart Disease I: Introduction
Cardiomyopathy I: Introduction and Classification